Background: Prostate-specific antigen (PSA) is an established tumor marker for the diagnosis of patients with prostate cancer. The aim of the study was to evaluate the performance of [-2]proenzyme PSA ([-2]proPSA) and prostate health index (PHI) tumor markers in the differential diagnosis between benign prostatic diseases and prostate cancer. Methods: Total PSA (tPSA), free PSA (fPSA) and [-2]proPSA were measured using antibody-based sandwich enzymelinked immunosorbent assay with a chemiluminescent detection system in 110 patients, with a tPSA of 1.6-8.0 µg/L. The PHI and %[-2]proPSA were calculated from the PSA values mentioned above. The results were compared with histopathological examination results following a transrectal ultrasound-guided biopsy of the prostate. Results: For the prediction of a malignant histopathological result, the specificity at the 90% sensitivity level was 24.3% for [-2]proPSA, 32.4% for %[-2]proPSA, 28.4% for PHI, 18.9% for tPSA and 28.4% for the free-to-total PSA ratio. The area under the curve for [-2]proPSA, %[-2] proPSA, PHI, tPSA and the free-to-total PSA ratio was 0.663, 0.749, 0.742, 0.616 and 0.625, respectively. Conclusions: Our study found a moderate improvement over tPSA and %fPSA in detecting prostate cancer using the [-2]proPSA assay in patients with a tPSA range of 1.6-8.0 µg/L.
Introduction
Prostate cancer (PCa) is the most frequent cancer among males and the second most common cause of death in men in the USA and the EU [1, 2] . The incidence rate of PCa has increased dramatically in the last 25 years due to the adoption of the tumor marker prostate specific antigen (PSA) into clinical practice [3] .
PSA is the most widely used serum tumor biomarker for the early detection of PCa. PSA is an organ-but not a cancer-specific tumor marker. Besides PCa, PSA levels are also elevated in acute prostatitis and benign prostatic hyperplasia (BPH) [4] . This limitation in specificity leads to substantial rates of false positive results from PSA tests, resulting in unnecessary prostate biopsies, especially in the PSA range of 4-10 µg/L.
Several PCa biomarkers were evaluated to overcome these limitations of PSA [5] . One of these markers is PSA circulating in the unbound form -free PSA (fPSA), which is used in calculating the percentage of fPSA against the total PSA (tPSA) ratio (%fPSA), which helps distinguish benign conditions from prostate cancer [6] .
Molecular isoforms of PSA are intensively investigated as possible effective tools for the early diagnosis of PCa [7] . Free PSA is a mixture of circulating inactive forms unattached to plasma proteins. fPSA includes the subforms BPH-associated PSA (BPSA), inactive PSA (iPSA) and proenzyme PSA (proPSA) [8, 9] . BPSA and iPSA are associated with benign tissue, while proPSA is considered a promising PCa serum marker [10, 11] . Four different proPSA isoforms exist in serum, named [-2]proPSA, [-4 ]proPSA, [-5] proPSA and [-7] proPSA depending on whether the length of the pro-leader peptide sequences is seven, five, four or two amino acids [12] . [-2] proPSA was found to be more accurate than tPSA and fPSA in differentiating PCa from benign disease in a prospective prostate cancer screening study in patients with PSA ranging from 2 to 10 µg/L. [-2] proPSA showed a higher specificity compared to tPSA and emerged as a promising marker for PCa detection [12] [13] [14] .
The [15] . Several investigations showed that [-2]proPSA, %[-2] proPSA and PHI are higher in PCa than in benign prostate conditions and that their use significantly improved cancer detection compared to tPSA and %fPSA [16, 17] , also having the potential of decreasing the number of unnecessary (negative) prostate biopsies [18, 19] . Furthermore, PHI seems to be associated with PCa aggressiveness and might guide the selection of patients suitable for active surveillance PCa protocol and determine the point at which radical PCa therapy should be offered to these patients [15, 20] .
The aim of our study was to evaluate the [-2]proPSA and PHI tumor markers in the differential diagnosis between benign prostatic diseases and PCa and compare it with PSA, an established clinical marker.
Materials and methods

Patients
The study was approved by the National Medical Ethics Committee of the Republic of Slovenia and complied with the principles of the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects. An informed consent was obtained from each participant. The study was conducted at the urological departments of two Slovenian University medical centres in Ljubljana and Maribor. Patients included in the study were routinely scheduled for transrectal ultrasound-guided biopsy (TRUS) of the prostate by the referring urologist due to an elevated PSA concentration (ranging between 1.6 and 8.0 µg/L). The exclusion criteria were a history of previous malignant disease, an indwelling urinary catheter, a previous positive biopsy for PCa, medical therapy involving dutasteride, finasteride or androgen replacement, a history of instrumental procedures on the lower urinary tract that increase PSA levels up to 3 months before sample collection, an inconclusive histopathological result, a history of transurethral resection of the prostate or open prostatectomy and acute prostatitis.
A total of 110 patients were prospectively enrolled in our study from January 2013 to September 2014.
Detection methods
A blood sample for analysis was obtained just before TRUS and was allowed to clot before the serum was separated by centrifugation. Serum samples were centrifuged and frozen at −20 °C within at least 3 h of blood drawing [21] Before the biopsy, digital rectal examination of the prostate was performed and the volume of the prostate was measured by a TRUS examination. TRUS was performed using the protocol established in both institutions, targeting the lateral parts of the peripheral zone of both prostatic lobes. Ten biopsy cores were taken in each patient.
Biopsy cores were analyzed in the histopathology laboratory of the Institute for Pathology at the Medical Faculty of Ljubljana, Slovenia and the Department of Pathology of the University Medical Center Maribor, Slovenia. Reported results were divided into a noevidence-of-malignancy (NOMA) category [BPH, prostatitis and highgrade prostatic intraepithelial neoplasia (HGPIN)] and a malignant (PCa and suspicious of PCa) category.
Statistical analysis
Data was analyzed using SPSS v.21.0 (IBM Corp., Armonk, NY, USA) and MedCalc v 16.4.3 (Software bvba, Ostend, Belgium). The measured concentrations of tPSA, fPSA, [-2]proPSA, %fPSA, %[-2]proPSA and PHI were compared using the Mann-Whitney U test for the two groups of patients.
tPSA, fPSA, [-2]proPSA, %fPSA, %[-2]proPSA and PHI were compared by calculating specificity at the 90% and 95% sensitivity levels and cut-off values were determined.
The performance of the tumor markers was also compared based on the receiver operating characteristic (ROC) curve by calculating the area under the curve (AUC) for each tumor marker, and pairwise comparison of the ROC curves was performed with the method of DeLong et al.
Results
Out of 110 patients, 74 had no evidence of malignancy in histopathology and in 36, PCa was found. There were 48 (64.8%) patients with BPH, 17 (23.0%) with prostatitis and 9 (12.2%) with HGPIN in the NOMA group. In the malignant group, two patients (5.6%) had a suspicious-of-PCa histopathological result, 16 patients (44.4%) had Gleason 6 PCa, 11 patients (30.6%) had Gleason 7 PCa, three patients (8.3%) had Gleason 8 PCa and in four patients (11.1%), Gleason 9 PCa was found. The age and prostate volume were significantly different between the NOMA and malignant groups of patients (Table 1) .
The values of the tumor markers in the study were statistically significantly different between the groups of patients with NOMA and malignant histopathological results, except for the concentration of fPSA, for which no significant difference was confirmed (Table 2) . %[-2]proPSA was found to have the highest specificity of 32.4% and 14.8% of the tumor markers in the study, at 90% and 95% sensitivity, respectively, followed by PHI and %fPSA with equal specificity of 28.4% and 12.2% at 90% and 95% sensitivity, respectively (Table 3) .
%[-2]proPSA was found to have the largest AUC of all the tumor markers in the study, closely followed by PHI. The serum concentrations of tPSA and %fPSA had nearly the same performance, while the AUC for the concentration of fPSA was low (0.518) ( Table 4 and Figure 1 ).
Pairwise comparison of ROC curves showed statistically significant differences between the AUC for %[-2] proPSA against tPSA, fPSA and %fPSA, and PHI against fPSA and %fPSA (Table 5) .
Discussion
The present study has focused on the performance of [-2] proPSA as a novel tumor marker for PCa. Ideally, a disease marker should have high sensitivity complemented by high specificity in order to identify as many patients with a disease as possible, while simultaneously preventing healthy subjects being subjected to unnecessary invasive and costly procedures. tPSA -an established PCa marker -was found to have a specificity of only 18.9% at the 90% sensitivity level, which is a minimal acceptable sensitivity level for a tumor marker. The main reason for the low specificity at the required sensitivity levels stems from the fact that tPSA is organ-specific but not PCa-specific [4] . A considerable number of men in the general population have tPSA elevation due to BPH. Bohnen et al. have shown that 72% of men in the general population with no PCa and tPSA between 2.1 and 2.5 µg/L had a prostate volume above 30 cm 3 and 66% of men with tPSA between 7.1 and 10.0 µg/L had a prostate volume above 50 cm 3 [22] . In our study, [-2]proPSA was also detected in men with NOMA prostate disease; however, it was significantly higher in PCa patients (median concentrations 10.33 ng/L vs. 13 .64 ng/L, p = 0.006). When [-2]proPSA was normalized through fPSA and tPSA in %[-2]proPSA and PHI, the difference was even more significant (p = 0.000), resulting in improvement of sensitivity and specificity against tPSA and fPSA. A meta-analysis of 17 studies with 6912 participants found high sensitivities for [-2]proPSA, %[-2]proPSA and PHI (90%, 89% and 90%, respectively), while specificities were low (13%, 32% and 31%, respectively) [23] . In contrast, our results show higher specificity for [-2]proPSA (24.3%) and comparable specificity for %[-2]proPSA and PHI (32.4% and 28.4%, respectively) at the 90% sensitivity level. Reported values of sensitivity/specificity among different studies are largely dependent on the selection of the cut-off concentration of tumor markers, which is often dictated by the aim of the study. Lowering the cut-off concentration increases sensitivity but decreases specificity. In the above meta-analysis, the reported cut-off concentrations of [-2] proPSA were in the range of 7-9 ng/L [23] , which is comparable with our study, where the cut-off concentration of [-2] proPSA at 90% sensitivity was 8.0 ng/L.
Calculating the ROC curve and AUC allows for comparison of the performance of different tumor markers in the study and across studies without the bias introduced by setting the cut-off concentration. The AUC of tPSA (0.616) in our study was not significantly different from [24] . One of the reasons for the improved performance of [-2]proPSA and its derivatives is its differential distribution in anatomical prostate zones. While tPSA does not seem to be differentially distributed in prostate zones, [-2] proPSA is elevated in cancerous and noncancerous parts of the prostate peripheral zone (PZ), but almost no [-2]proPSA (< 0.2%) is present in the prostate transition zone (TZ) [10] . In contrast, BPSA is found predominantly in the TZ of patients with nodular BPH in patients with or without PCa [25] . When the main source of increased PSA is TZ, as in BPH, [-2] proPSA, %[-2]proPSA and PHI remain low, whereas in patients with PCa, which predominantly grows in the PZ, [-2]proPSA, %[-2]proPSA and PHI are significantly higher. When [-2]proPSA is produced exclusively in cancerous parts of the PZ, it would represent an ideal tumor marker with nearly 100% sensitivity and specificity limited only by the sensitivity of the marker laboratory assay to detect even minimal concentrations produced by cancerous cells.
Conclusions
Our study found a moderate improvement over tPSA and %fPSA in detecting PCa using the [-2]proPSA assay and PHI in patients with a tPSA range of 1.6-8.0 µg/L. Its adoption into clinical practice depends on cost-effectiveness and on the rate of development of new genetically based PCa markers, for example microRNAs, which promise nearly ideal performance (AUC = 0.989) when used in panels [26] . Not all studies, however, have found microRNAs to have such perfect performance, and some studies failed to find clinical value of these markers in PCa [27, 28] .
